The critical challenge in abdominal aortic aneurysm (AAA) research is the accurate diagnosis and assessment of AAA progression. Angiogenesis is a pathological hallmark of AAA, and CD105 is highly expressed on newly formed vessels. Our goal was to use 
INTRODUCTION
Abdominal aortic aneurysm (AAA) is a common and potentially lethal vascular disease more prevalent in men over the age of 65. It is characterized by progressive expansion and weakening of abdominal aortic wall (1) (2) (3) . Advanced AAA usually leads to rupture, which represents a leading cause of death in the Western world. In the United States, there are approximately 30,000 deaths every year because of AAA, and 15,000 of these are related to rupture of AAA (3, 4) .
Although the techniques for effective diagnosis and treatment of AAA are urgently needed, noninvasive imaging of AAA at molecular/cellular level is still underexplored, which has attracted tremendous interest from the research community. Several tracers, e.g. in previous studies. However, the reliability of conventional tracers is still under debate (11) , and there is need for new and more reliable molecular targets and tracers for PET imaging of AAA.
Angiogenesis has been proven to be a pathological hallmark of AAA in both human and animal models, and it plays an important role in the development and progression of AAA (12) (13) (14) (15) . Higher levels of neovascularization are detected at the rupture edge in aortic aneurysm, suggesting that imaging of molecules and processes involved in angiogenesis can potentially depict high-risk aneurysms (16) . One important advantage of targeting angiogenesis is that rapid, persistent and specific targeting can be achieved with different probes, which endows an excellent efficiency and imaging contrast. The endothelial cells of newly formed vessels express high levels of CD105, also known as endoglin, on their surfaces (17). We have previously demonstrated the efficacy of a CD105 targeted antibody, TRC105, for in vivo imaging of angiogenesis (18-21). Therefore, we hypothesize that CD105 could act as a promising target for imaging and even for treatment of AAA.
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Our goal is to investigate a novel probe for effective targeting and imaging of AAA with excellent targeting specificity and imaging contrast. To achieve this goal, we have employed a 64 Cu-labeled TRC105 Fab fragment (i.e. 64 Cu-NOTA-TRC105-Fab) as a probe for PET imaging of AAA. Compared with TRC105 full antibody, TRC105-Fab could be rapidly cleared by kidneys with shortened circulation half-life (22), which might result in superior imaging contrast in the abdominal area. To the best of our knowledge, this is the first report of AAA PET imaging with an antibody fragment-based probe.
MATERIALS AND METHODS

Chemicals
TRC105 was provided by TRACON Pharmaceuticals, Inc. Rat anti-mouse CD31 primary antibody was purchased from BD Biosciences. AlexaFluor488-and Cy3-labeled secondary antibodies were purchased from Jackson Immunoresearch Laboratories, Inc. S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) was purchased from Macrocyclics, Inc. Fluorescein isothiocyanate (FITC) and chelex 100 resin (50-100 mesh) were acquired from Sigma-Aldrich. PD-10 desalting columns were purchased from GE Healthcare. All other reaction buffers and chemicals were from Thermo Fisher Scientific. 
AAA Animal Models
AAA was induced by topical application of calcium phosphate in four-to five-week-old female BALB/c mice (Harlan) under anesthesia (2-4% isofluorane) as described previously (28).
Briefly, the abdominal cavity was opened with a midline abdominal incision. The infrarenal region of the abdominal aorta was freed from the surrounding adipofascial tissue by gentle dissection, and a small piece of 0.5 mol/L CaCl 2 -soaked gauze was applied for 10 min to aorta followed by application of another piece of PBS-soaked gauze for 5 min. Mice in sham group were only treated with PBS for 15 min. All animal studies were conducted under a protocol approved by the University of Wisconsin Institutional Animal Care and Use Committee.
Radiolabeling, PET Imaging and Biodistribution Studies of NOTA-TRC105-Fab
64
Cu was produced by a GE PETrace cyclotron using the 64 Ni(p,n) 64 Cu reaction. reconstruction, and region-of-interest (ROI) analysis of the PET images were carried out as previously described (22, 29) . After the last scan at 24 h p.i. on Day 12, biodistribution studies were performed to corroborate PET data. Aorta, blood and major organs/tissues were collected and wet-weighed. The radioactivity in the tissue was measured using a γ counter (PerkinElmer) and presented as %ID/g (mean ± SD).
Ex Vivo Imaging and Histology
The infrarenal portion of the abdominal aorta was collected from the animals following euthanasia. Autoradiographic images of the collected aortas were obtained using a gamma camera. The aortas were frozen and cryo-sectioned for histological analysis. Haematoxylin/eosin (HE) staining was performed to observe the microscopic changes in the abdominal aortic wall, 
RESULTS
Generation and Characterization of TRC105-Fab
The elution profile of the TRC105-Fab showed a narrow peak in UV intensity between 16-18 mL, which indicated a high purity (Fig. 1A) . This fraction was used for further studies. A narrow band corresponding to a molecular weight of 50-55 kDa was observed in SDS-PAGE (Fig. 1B) , further confirmed the purity of TRC105-Fab.
Flow Cytometry
CD105 is highly expressed on human umbilical vein endothelial cells (HUVECs) (27). Our previous studies have documented that TRC105 possesses superior binding affinity and specificity to CD105 (20, 27, 30) . Flow cytometry was used to examine the targeting efficiency of TRC105-Fab in vitro. After the treatment with 5 ug/mL FITC-TRC105-Fab, the fluorescence signal from the HUVECs exhibited ~ 4-fold increase over the negative control (PBS treated HUVECs) (Fig 1C) , indicating that TRC105-Fab could efficiently bind to CD105, although with a lower binding affinity than the intact antibody. In addition, a similar increase was observed after incubating the cells with 5 ug/mL FITC-TRC105-Fab-NOTA, suggesting that NOTA conjugation does not compromise the binding affinity of FITC-TRC105-Fab.
PET Imaging and Biodistribution Studies
On Day 5 following AAA induction, a significantly higher tracer uptake was observed in the aortic region of the animals from AAA group as early as 0.5 h p.i. which remained relatively stable up to 24 h p.i. (9.4 ± 0.1, 9.3 ± 0.7, 9.5 ± 0.4, 7.9 ± 0.5, 7.9 ± 0.4 %ID/g at 0.5, 3, 6, 16, and 24 h p.i., respectively; n = 3; Fig. 2 and 4A) . On Day 12, the uptake in aortas of the animals from AAA group was still high (8.0 ± 1.5, 7.9 ± 1.2, 7. Fig. 2, 3, 4A and B) . Taken together, a great enhancement in aortic uptake was achieved in an AAA animal model using 64 Cu-NOTA-TRC105-Fab, suggesting its superior efficiency and specificity in CD105 targeting.
The signals from normal tissues were similar in AAA, blocking and sham groups at all time points (Fig. S1) , indicating consistent pharmacokinetics of 64 Cu-NOTA-TRC105-Fab and accuracy of ROI analysis. 64 Cu-NOTA-TRC105-Fab yielded low levels of background signal in abdominal area probably because it was mainly cleared though the kidneys ( Fig. 2 and 3 The data clearly demonstrates that excellent imaging contrast can be achieved in AAA with 64 Cu-NOTA-TRC105-Fab probe.
To confirm the accuracy of PET images and ROI analysis, mice in all three groups were sacrificed at 24 h p.i. on Day 12. Aorta and other major organs were collected and the radioactivity signals were measured with a gamma counter. The quantitative data from biodistribution and ROI analysis matched well (Fig. 5) . Of note, kidney uptake was significantly higher than the liver uptake in biodistribution study, which further validates the renal clearance 
Ex Vivo Imaging and Histology
A macroscopically visible aneurysmal dilation was observed in the abdominal aortas of mice from AAA group 5 days after induction (Fig S2) . Ex vivo autoradiography revealed a higher signal in the aortas from AAA group than the aortas from blocking and sham groups (Fig. 6A) , further confirming the accuracy of the results from PET imaging, ROI analysis and biodistribution studies. Flattening and degradation of the elastic lamina due to increased diameter was obvious in HE staining of dilated aorta (Fig. 6B) . The external diameter of aorta was 0.9 ± 0.1 mm in AAA group on Day 5, whereas it was only 0.4 ± 0.01 mm in normal aorta.
The intensity of CD105 immunofluorescence was highest on Day 5 suggesting active angiogenesis after AAA induction (Fig. 6C) . The fluorescence intensity was similar to normal aorta on Day 12. These results correlated well with PET imaging results. Taken together, CD105 was highly expressed in AAA at Day 5 after induction, accompanied with structural change of aortic wall, matching well with in vivo and ex vivo studies.
DISCUSSION
In management of AAA clinicians are often faced with the important decision of whether to perform invasive repair or to manage the condition conservatively. This obstacle arises from the lack of methods that enables non-invasive acquisition of molecular/cellular information in the developing AAA. Current guidelines recommend endovascular repair or surgery if the aortic diameter exceeds 5.5 cm and follow-up with anatomic imaging every 3 to 6 months for aneurysms above 4 cm. However, the size of AAA is neither the sole nor the most accurate determinant for the risk of rupture (31). Individual risk is also influenced by gender, age, smoking, and comorbidities, but its assessment is rarely easy because reliable methods for the optimal evaluation of these variables are not readily available. This situation often leads to difficulties in decision making, and many patients are unnecessarily exposed to the risks of reparative surgery when their aneurysm might never have ruptured if left untreated (32). Serial monitoring of the biological activity of AAA would be ideal to identify high-risk patients and prompt earlier therapy to prevent rupture while also sparing low-risk patients from expensive and morbid procedures (33).
To date, PET imaging of AAA has been mostly performed with negative results. We also tested the imaging capacity of 18 F-FDG in AAA in this study, but we could not detect a significant difference between aortic signals in normal mice and mice with AAA ( Fig. S3 and S4 ). In the contrary, the increased expression of CD 105 in AAA could be detected with high sensitivity and specificity using TRC105-Fab. CD105 is expressed on inflamed and some normal tissues to a certain extent, but the expression on endothelial cells is significantly higher (40). Therefore, CD105 has been accepted as an important angiogenesis The limitation to current preliminary study is the experimental AAA model. Although murine model has biological features found in human AAA (28), it does involve aortic dissection as part of the AAA expansion process and may not be ideal to study AAA rupture. Moreover, murine AAA develops over weeks, rather than decades, so the model might not fully represent human AAA in terms of biology and progression (33). Prospective outcome studies are needed first with more clinically relevant animal models of AAA and eventually in patients. These trials will determine whether an increased PET signal, despite the limited spatial resolution of PET, can indeed predict aneurysm rupture.
CONCLUSION
In this study, we demonstrated an increased expression of CD105 in AAA and defined a novel, high specify, high sensitivity probe for the in vivo PET imaging of AAA with TRC105-Fab. More importantly, we achieved an exquisite imaging contrast due to the low background in the abdominal area. The as-designed imaging probe might open new avenues into AAA research, which will eventually benefit the healthcare of whole AAA patient population.
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